PMID- 9193359
OWN - NLM
STAT- MEDLINE
DCOM- 19970710
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 15
IP  - 4
DP  - 1997 Apr
TI  - Allogeneic-blood stem-cell collection following mobilization with low-dose 
      granulocyte colony-stimulating factor.
PG  - 1601-7
AB  - PURPOSE: The optimal dose of granulocyte colony-stimulating factor (G-CSF) for 
      mobilization of allogeneic-blood stem cells (AlloBSC) has yet to be determined. 
      As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched 
      donors had blood cells mobilized with G-CSF at 5 micrograms/kg/d by subcutaneous 
      administration. The purpose of this trial was to monitor adverse effects during 
      G-CSF administration and stem-cell collection, to determine the optimal timing 
      for stem-cell collection, and to determine the cellular composition of stem-cell 
      products following G-CSF administration. PATIENTS AND METHODS: The median donor 
      age was 42 years. Apheresis began on day 4 of G-CSF administration. At least 
      three daily 12-L apheresis collections were performed on each donor. A minimum of 
      1.0 x 10(6) CD34+ cells/kg (recipient weight) and 8.0 x 10(8) mononuclear 
      cells/kg were collected from each donor. All collections were cryopreserved in 5% 
      dimethyl sulfoxide and 6% hydroxyethyl starch. RESULTS: Toxicities associated 
      with G-CSF administration and the apheresis process included myalgias/arthralgias 
      (83%), headache (44%), fever (27%), and chills (22%). The median baseline 
      platelet count of 242 x 10(4)/ mL decreased to 221, 155, and 119 x 10(6)/mL on 
      days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ 
      cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 10(6)/kg, 
      respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells 
      remained relatively constant during the three collections. Median total numbers 
      of cells were as follows: CD34+, 7.73 x 10(6)/kg; and lymphocytes, 6.93 x 
      10(8)/kg. CONCLUSION: Relatively low doses of G-CSF can mobilize sufficient 
      numbers of AlloBSC safely and efficiently.
FAU - Bishop, M R
AU  - Bishop MR
AD  - Department of Internal Medicine, University of Nebraska Medical Center, Omaha 
      68198-3330, USA. MRBishop@mail.UNMC.edu
FAU - Tarantolo, S R
AU  - Tarantolo SR
FAU - Jackson, J D
AU  - Jackson JD
FAU - Anderson, J R
AU  - Anderson JR
FAU - Schmit-Pokorny, K
AU  - Schmit-Pokorny K
FAU - Zacharias, D
AU  - Zacharias D
FAU - Pavletic, Z S
AU  - Pavletic ZS
FAU - Pirruccello, S J
AU  - Pirruccello SJ
FAU - Vose, J M
AU  - Vose JM
FAU - Bierman, P J
AU  - Bierman PJ
FAU - Warkentin, P I
AU  - Warkentin PI
FAU - Armitage, J O
AU  - Armitage JO
FAU - Kessinger, A
AU  - Kessinger A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Flow Cytometry
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Hematopoietic Stem Cells/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Tissue Donors
MH  - Transplantation, Homologous
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1200/JCO.1997.15.4.1601 [doi]
PST - ppublish
SO  - J Clin Oncol. 1997 Apr;15(4):1601-7. doi: 10.1200/JCO.1997.15.4.1601.